Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies
Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Marcella Mottolese, Giulio Metro(University of Perugia), Alessandra Felici, G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Diana Giannarelli(Agostino Gemelli University Polyclinic), Paolo Carlini(National Cancer Institute)
Cited by 52
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240